A detailed history of Versant Venture Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Versant Venture Management, LLC holds 498,558 shares of CRSP stock, worth $20.4 Million. This represents 61.4% of its overall portfolio holdings.

Number of Shares
498,558
Previous 498,558 -0.0%
Holding current value
$20.4 Million
Previous $26.9 Million 13.0%
% of portfolio
61.4%
Previous 59.79%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$110.2 - $156.64 $1.1 Million - $1.57 Million
-10,000 Reduced 1.97%
498,558 $55.8 Million
Q2 2021

Aug 12, 2021

SELL
$100.84 - $161.89 $106 Million - $169 Million
-1,046,402 Reduced 67.29%
508,558 $82.3 Million
Q1 2021

May 07, 2021

SELL
$110.72 - $210.04 $164 Million - $312 Million
-1,485,502 Reduced 48.86%
1,554,960 $189 Million
Q4 2020

Feb 16, 2021

SELL
$79.67 - $173.23 $47.1 Million - $102 Million
-591,194 Reduced 16.28%
3,040,462 $466 Million
Q3 2020

Nov 12, 2020

SELL
$78.5 - $100.64 $43.3 Million - $55.5 Million
-551,408 Reduced 13.18%
3,631,656 $304 Million
Q2 2020

Jul 20, 2020

SELL
$38.5 - $76.05 $868,213 - $1.72 Million
-22,551 Reduced 0.54%
4,183,064 $307 Billion
Q4 2019

Jan 21, 2020

SELL
$36.68 - $73.13 $1.04 Million - $2.07 Million
-28,255 Reduced 0.67%
4,205,615 $256 Billion
Q3 2019

Oct 08, 2019

SELL
$40.99 - $52.56 $615,587 - $789,346
-15,018 Reduced 0.35%
4,233,870 $174 Billion
Q1 2019

Apr 05, 2019

BUY
$28.02 - $40.87 $17.9 Million - $26.2 Million
640,014 Added 17.73%
4,248,888 $152 Billion
Q2 2018

Jul 13, 2018

SELL
$42.62 - $73.59 $42.5 Million - $73.4 Million
-997,368 Reduced 21.65%
3,608,874 $212 Billion
Q1 2018

May 03, 2018

BUY
$23.52 - $58.17 $108 Million - $268 Million
4,606,242 New
4,606,242 $211 Billion

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.19B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Versant Venture Management, LLC Portfolio

Follow Versant Venture Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Venture Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Versant Venture Management, LLC with notifications on news.